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EDITORIAL REVIEW
Mechanism of the antimineralocorticoid effects of spirolactones
P. CORVOL, M. CLAIRE, M. E. OBLIN, K. GEERING, and B. RossIER
Spirolactones are antimineralocorticoid compounds, which
were introduced into therapeutics in 1960. They are useful in
the treatment of hyperaldosteronism and essential hyperten-
sion, although their side effects (gynecomastia, impotence,
menstrual cycle abnormalities) limit their use. They are known
to antagonize the effect of aldosterone at the level of the target
cells, and until recently this mechanism was the only one
generally implicated. In 1972, Erbier showed that spironolac-
tone inhibits aldosterone biosynthesis in vitro [1]. Since then,
several authors have confirmed this effect, both in animals and
man, and have therefore challenged the relative importance of
peripheral aldosterone antagonism in favor of an inhibitory
effect of these drugs on aidosterone biosynthesis.
This editorial review attempts to clarify the findings and to
determine whether antialdosterones act mainly at the target
cell, or through inhibition of aldosterone production, or alterna-
tively by a combination of each effect.
Action of spirolactones on mineralocorticoid receptors
Aldosterone is thought to induce a three step cascade of
events [2]: (1) stereospecific binding of aldosterone to a cyto-
plasmic receptor followed by translocation of the steroid recep-
tor complex into the nucleus, where it interacts with specific
sites of the genome, (2) induction of the synthesis of mRNA or
rRNA, and (3) translation of the induced mRNA into specific
proteins, which, in turn, directly or indirectly increase sodium
reabsorption (and/or potassium or hydrogen ion secretion)
across the epithelial cells of target organs such as mammalian
renal tubules or amphibian urinary bladder. General reviews of
this mechanism have recently been published [3, 4] and articles
dealing specifically with the mineralocorticoid receptor [5], the
role of RNA [6], or the aldosterone-induced proteins [7] are also
available.
The possibility that a steroid hormone could directly compete
with aldosterone at the level of the target cells was first
suggested by Sala and Luetscher, who found that cortisone
inhibited the antinatriuretic effect of injected aldosterone in rats
[8]. Landau et al [9] described in 1955 that progesterone blocked
the sodium-retaining action of aldosterone in a patient with
Addison's disease. In adrenalectomized rats, Celia and Kagawa
(1957) subsequently demonstrated that steroidal derivatives,
the spirolactones, act by a similar mechanism, that is, by direct
competition with aldosterone at the target cell level [10]. Since
that time, a great number of clinical or experimental studies
have provided evidence that the spirolactones are specific
competitive antagonists of aldosterone at the level of the
mineralocorticoid receptor (for review, see Refs. 11—14). Before
accepting these conclusions, it is necessary to examine careful-
ly the pharmacologic data indicating that spirolactones are
specific competitive antagonists and to consider the various
molecular mechanisms by which spirolactones could act.
(1) Spirolactones: specific competitive antagonists? Specific
competitive antagonists should fulfill the following criteria: (1)
dose-dependent antagonistic activity inducing a decrease in the
potency of the antagonist, (2) specificity, and (3) competitive
interaction at the receptor level.
For studying the action of aldosterone and spirolactones, two
experimental models have been used most extensively: the
adrenalectomized rat and the urinary bladder of the toad.
(a) Antagonistic activity. It is well established that, in the
adrenalectomized rat, aldosterone induces a sodium reabsorp-
tion and a potassium excretion [10, 16]. A direct effect on
hydrogen ion excretion has also been suggested [17]. For
practical reasons, the urinary sodium/potassium concentration
ratio in 4-hour urine samples from adrenalectomized rats has
generally been used as a screening test for mineralocorticoid
and antimineralocorticoid activity (Kagawa's test [18]). In this
model, spirolactones enhance the urinary sodium-potassium
ratio previously depressed by the administration of mineralo-
corticoids. The expected dose-response curve is obtained for
competitive inhibition.
In the toad bladder, aldosterone enhances sodium reabsorp-
tion without effect on potassium ion movement, but two studies
have shown increased hydrogen ion secretion in toad and turtle
bladders [19, 20]. Spirolactones inhibit, in a dose-dependent
manner, the aldosterone-induced sodium reabsorption as mea-
sured by the short-circuit current method [12, 19]. Using
Lineweaver-Burk plots of changes in short-circuit current,
Porter and Kinsey showed that SC 19886 (Fig. 1) was able to
competitively inhibit the aldosterone-stimulated sodium trans-
port [21].
One striking finding that emerges from various studies is that
the spirolactones display no or very little agonistic activity on
urinary sodium-potassium ratios in the adrenalectomized rat.
At very high doses, some spirolactones such as SC 8109 show a
small but significant agonistic activity and, thus, are "partial"
antagonists [22]. In the toad, which cannot be adrenalecto-
mized, the secretion of endogenous aldosterone can only be
partially suppressed by soaking the animals in saline solution
[23]. Thus, the urinary bladder used in vitro for testing the
agonistic and antagonistic activity is exposed to variable
amounts of aldosterone before removal. This fact might explain
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Fig. 1. Structures of aldosterone antagonists described in the text.
the observation that spirolactones (up to 25 M) either had no
agonistic action or depressed to some extent the sodium trans-
port baseline [24]. In one study [25], two spirolactones SC
26304 and prorenone (SC 23133) were found to have a small but
significant agonistic effect. This effect could not be reproduced,
however, in another study concerning prorenone [14], and the
general conclusion is that most spirolactones, including spiron-
olactone, lack agonistic activity. This feature is in general not
shared by other antisteroid drugs; for example, the antiestrogen
nafoxidin [26] or the antiglucocorticoid cortexolone (see review
[27]) have significant agonistic activity.
In both experimental systems the antagonistic action of
spirolactones is fully reversible upon further addition of aldos-
terone, indicating that the antagonist does not bind to the
receptor in an irreversible manner [11, 14].
(b) Specificity. Spirolactones block the effect of various
mineralocorticoids such as deoxycorticosterone [18] and aldos-
terone [18, 28]. This property permits a convenient and repro-
ductible bioassay in man: spirolactones reverse the sodium-
retaining and potassium-excreting effect of 9a-fluorohydrocorti-
sone [29]. Specificity for mineralocorticoid effects is also shown
by the fact that spironolactone acts differently from amiloride in
toad bladder [30]. Moreover, in this model the effect of vaso-
pressin, which enhances sodium reabsorption to the same
extent as aldosterone but by a different mechanism involving
cyclic AMP, is not inhibited by spironolactone [31].
(c) Action at the receptor level and structure-activity rela-
tionship. Mineralocorticoid binding sites have been identified
and characterized in a number of target organs, both in mam-
mals and amphibians. Two types of binding sites have been
described: type I displays affinity constants, which make them
good candidates for mineralocorticoid receptors, whereas type
II could represent glucocorticoid receptors [32—35]. Several
studies show that spirolactones can compete for the type I
binding sites [36—39].
In vivo, spirolactones are not very potent drugs because high
molar antagonist/agonist ratios are required for producing an
effect. Thus, in the adrenalectomized rat, a dose of S mg of
spironolactone per kilogram of body wt must be given to
antagonize the effect of I p.g of aldosterone acetate per kilogram
of body wt [28]. This dose is much higher than that expected
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Fig. 2. Comparison of in vivo and in Vitro activity of three spirolactones:
(a) Percentage of increase in sodium-potassium ratio compared with
the aldosterone-treated reference group; (b) Percentage of the competi-
tive potency of aldosterone taken as reference. The 100% corresponds
to the concentration ratio of unlabeled to 3H-aldosterone needed to
obtain 50% inhibition of binding to mineralocorticoid sites. (Data is
from Peterfalvi et at [30].)
from receptor studies because spirolactones generally exhibit a
high affinity for the mineralocorticoid receptor [28, 40]. Drug
metabolism to less active or inactive metabolites partly ac-
counts for this apparent discrepancy [41]. Spironolactone is
dethioacetylated into canrenone (SC 9376), which exists in
equilibrium with canrenoate (SC 14266), the acid carboxylic
form [42]. In receptor studies [28, 39], canrenone has 10% of the
affinity of spironolactone for the aldosterone receptor, whereas
canrenoate does not bind to the receptors. The critical impor-
tance of the presence of the lactone ring for the binding of
spirolactones to receptors has been demonstrated using methyl-
ated canrenoate (Fig. 2), a canrenoate analog that is inactive
both in the rat kidney [28] and in the toad bladder (Rossier et al,
unpublished results).
(2) Mechanism of action of spirolactones at the receptor
level. Our understanding of the molecular mechanism of action
of spirolactones has recently progressed by the use of labeled
antagonists with high specific activity. Marver et al [43] first
demonstrated that in the rat kidney a 3H-labeled spirolactone
(SC 26304) bound to cytoplasmic proteins, which are probably
mineralocorticoid receptors. These investigators did not detect
any translocation of the antagonist-receptor complexes into the
nucleus under three different experimental conditions. Claire et
a! [40] obtained similar results with another labeled spirolac-
tone, 1,2,-3H-prorenone, which bound with high affinity to
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Fig. 3. Models for steroid agonist and antagonist mechanism of action
at the subcellular level: interactions with receptors and chromatin
acceptor sites. One asterisk (*) denotes the active form of the receptor;
two asterisks (**), the inactive form,
mineralocorticoid receptors (Kd = 1.6 X i0 M) [40]. Again,
the cytosolic 3H-prorenone receptor complex did not yield any
nuclear binding.
These results have been interpreted within the context of a
model proposed by Feldman, Funder, and Edelman [33] for the
interaction of aldosterone with its receptors (see Fig. 3). This
model can be useful for understanding the mechanism of action
of spirolactone. It implies the following assumptions: (1) pas-
sive diffusion of ligand across the outer plasma and the nuclear
membranes allowing complete equilibration between the extra-
cellular and the intracellular compartment, (2) presence of
receptors in two allosteric states in equilibrium: one active and
one inactive (in the presence of an agonist, the equilibrium is
shifted towards the "active" form; in the presence of an
antagonist, towards the "inactive" form), (3) free receptors are
unable to translocate into the nuclear compartment, (4) the
receptor-agonist complex translocating into the nucleus and
then (5) binding to specific acceptor sites on the chromatin. All
steps 1, 2, 4, 5 as well as recycling of the receptors in the
cytoplasm are assumed to be reversible.
Spirolactones could theoretically inhibit the action of aldos-
terone by four different mechanisms (Fig. 3). In the first one
(A), the antagonist receptor complex is supposed to be unable
to translocate into the nucleus. In mechanism B, translocation
occurs but the complex has little or no affinity for the chromatin
acceptor. In mechanism C, the antagonist receptor complex
also translocates into the nucleus, then binds to chromatin but
fails to trigger the transcription mechanism. Mechanism D
implies an impairment of receptor recycling, leading to cytoso-
lic receptor depletion.
The data obtained by Marver et al [43] and Claire et al [40]
favor the mechanism A, because there was no radioactive 3H-
spirolactone receptor complex found in the nuclei under differ-
ent conditions. But, as suggested by Claire et al, methodologic
artifacts such as redistribution of receptors during homogeniza-
tion and high nonspecific binding of spirolactones could explain
the absence of binding to chromatin. If not due to artifacts, this
absence of binding to chromatin could also be in favor of
mechanism B which has been postulated for cortexolone [27].
Mechanism C implies a high affinity binding of the antagonist-
receptor complex to the chromatin and can thus be ruled out.
Mechanism D which has been proposed for nafoxidin, an
antiestrogen [26], is not likely for the action of spirolactones
because no cytosolic receptor depletion was observed in the
study of Claire et al [40].
Inhibition of aldosterone biosynthesis by spirolactones
Spironolactone has first been shown to inhibit aldosterone
biosynthesis in incubated adrenal quarters in vitro by Erbler in
1972 [1]. Aldosterone synthesis stimulated by ACTH, potassi-
um, or angiotensin II was inhibited by l0- to l0- M spirono-
lactone. A dose-response curve was obtained from these stud-
ies, and Erbler concluded that spironolactone could block the
© conversion of corticosterone into aldosterone.
Since 1972, several authors have confirmed the inhibition of
aldosterone biosynthesis by spirolactones in adrenal prepara-
tions of human, bovine [44], duck [45], and guinea pig [46]. The
kinetics of the inhibition of aldosterone biosynthesis have been
investigated by Delarue et al [47] in an in vitro frog interrenal
perfusion model: the lag period between the infusion of the drug
and the beginning of the response was less than 10 mm.
Aldosterone output rose back to its initial value approximately
100 mm after stopping drug administration. Spirolactones and
their y carboxylic acid analogs share these effects.
(1) Site of action of spirolactones on steroid biosynthesis in
vitro. Spirolactones have been reported to act at different steps
of aldosterone biosynthesis (Fig. 4). Spironolactone, canren-
one, and K canrenoate inhibit mitochondrial ll3 and 18-
hydroxylase [44, 45, 48]. Canrenone appears to be the most
active compound and was found to be much more effective in
inhibiting 1 8-hydroxylases than were 11 p-hydroxylases in the
adrenals from patients with primary hyperaldosteronism [44].
But, the action of spirolactones is not limited to these hydroxy-
lases; pretreatment of guinea pig with spironolactone induces
an inhibition of adrenal 21-hydroxylase [46], and administration
of spironolactone to rats at high doses (200 mg/kg of body wt
per day) impaires the testicular l7a-hydroxylase [49]. Unlike
the structural requirement for receptor antagonism, antiste-
roidogenesis activity does not seem to be dependent on the
presence of a lactonic ring, but high concentrations (10 to
i0 M) of the inhibitors are always required to inhibit biosyn-
thesis.
Several molecular mechanisms have been proposed for the
effects of spirolactones on steroidogenesis. Erbler [50] suggest-
ed that canrenone might act as a false substrate for 11 3- and 18-
hydroxylases and, indeed, adrenal tissue hydroxylates canren-
one and other spirolactones [44]. A competitive type of inhibi-
tion has been suggested by Cheng for 18-hydroxylation [44] but
spirolactones may also inhibit hydroxylation by binding to
cytochrome P450 [44, 46] or even "destroy" the cytochrome
P450 of adrenal and testicular tissue when animals are pretreat-
ed with high doses [46, 49]. This latter effect, however, is
probably nonspecific because it is shared by other steroids that
do not affect steroidogenic tissue.
(2) Effect of spirolactones on aldosterone secretion in vivo.
Although spirolactones inhibit aldosterone biosynthesis in vi-
tro, their action on plasma aldosterone level is much more
controversial. That spirolactones might indeed block aldoster-
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Fig. 4. Effects of spirolactones at various steps of the biosynthesis of
aldosterone. The solid line (—) denotes the major inhibiting property;
the broken line (---), the other possible sites of action.
one biosynthesis in vivo came first from a study on a patient
with primary aldosteronism. In this study, SundQjord et al [51]
showed a decrease in aldosterone secretion rate during 4
month's treatment with doses up to 100 to 200 mgldaily. But, a
carefully controlled study performed on normal volunteers with
diuretic-induced secondary hyperaldosteronism demonstrated
only a transient effect of canrenone on plasma alclosterone
levels [52]. Similarly, Conn and Hinerman [53] found only an
early and transient decrease of urinary aldosterone during
spironolactone treatment of primary aldosteronism. In fact, the
authors noted that, in some cases, the observed decrease was
followed by an important increase (50 to 100%) in the aldoster-
one excretion. The same observation was made by Abshagen et
a! [54] for plasma aldosterone levels in normal subjects under
continuous spironolactone treatment: after 3 days, the aldoster-
one levels increased to the same extent as that in triamterene-
treated patients. Gaillard et al [55] also failed to observe a
depression of aldosterone secretion rate after the administration
of 400mg of spironolactone to normal young men and, instead,
obtained an increase of aldosterone secretion without any
change in aldosterone metabolism, cortisol secretion rate, or
plasma corticosterone concentration.
Increased plasma levels and urinary aldosterone excretion
induced by spironolactone were also described in long-term
studies performed on hypertensive patients [56] and rats [57].
An increase in aldosterone synthesis is not surprising and
would be expected in an endocrine mechanism regulated by
feedback control, when blockade of receptors occurs. Specifi-
cally, the natriuretic and diuretic effects of spirolactones can
depress plasma sodium, elevate plasma potassium, and activate
the renin-angiotensin system. The aldosterone increase mediat-
ed by these mechanisms could, of course, override an enzymat-
ic blockade of aldosterone biosynthesis.
Conclusions
From the experimental and clinical data analyzed in this
editorial, it appears that the natriuretic effect of spirolactones is
mainly, if not exclusively, due to its peripheral antagonism
against aldosterone:
(1) Doses required to inhibit aldosterone biosynthesis in vitro
are larger by several orders of magnitude than those required
for inhibiting receptor-binding of aldosterone. If spirolactones
were to act by inhibiting the biosynthesis of aldosterone, they
would, therefore, have to be concentrated at the sites of
aldosterone synthesis in the adrenal cortex, This possibility has
not been excluded to date.
(2) In vitro, spirolactones can affect nonspecifically several
hydroxylases that are involved not only in aldosterone but also
in glucocorticoid biosynthesis.
(3) Depression of aldosterone secretion has not always been
observed under short-term spirolactone treatment and, when
present, is transient and of small magnitude.
(4) During long-term spirolactone treatment in animals and
man, aldosterone levels are increased to the same extent as with
nonantialdosterone diuretic therapy.
These conclusions concerning the antialdosterone effect of
spirolactones probably also apply to the mechanisms of their
side effects. Spirolactones are potent antiandrogenic drugs at
the level of the dihydrotestosterone receptor [58, 59]. But here
again, spirolactones appeared to induce either a slight decrease
in plasma androgen levels [60] or even no alteration at all [61].
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